MX2022001328A - Inhibidor de proteina quinasa quinasa activada por mitogeno (mek) para el tratamiento de apoplejia. - Google Patents

Inhibidor de proteina quinasa quinasa activada por mitogeno (mek) para el tratamiento de apoplejia.

Info

Publication number
MX2022001328A
MX2022001328A MX2022001328A MX2022001328A MX2022001328A MX 2022001328 A MX2022001328 A MX 2022001328A MX 2022001328 A MX2022001328 A MX 2022001328A MX 2022001328 A MX2022001328 A MX 2022001328A MX 2022001328 A MX2022001328 A MX 2022001328A
Authority
MX
Mexico
Prior art keywords
treatment
stroke
mek inhibitor
sah
compositions
Prior art date
Application number
MX2022001328A
Other languages
English (en)
Inventor
Lars Edvinsson
Original Assignee
Edvince Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Edvince Ab filed Critical Edvince Ab
Publication of MX2022001328A publication Critical patent/MX2022001328A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a un inhibidor de MEK y composiciones del mismo, para ser utilizados en el tratamiento de apoplejía, en particular tratamiento de hemorragia subaracnoidea (SAH).
MX2022001328A 2019-07-30 2020-07-28 Inhibidor de proteina quinasa quinasa activada por mitogeno (mek) para el tratamiento de apoplejia. MX2022001328A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19189069 2019-07-30
PCT/EP2020/071209 WO2021018866A1 (en) 2019-07-30 2020-07-28 Mek inhibitor for treatment of stroke

Publications (1)

Publication Number Publication Date
MX2022001328A true MX2022001328A (es) 2022-05-20

Family

ID=67513366

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001328A MX2022001328A (es) 2019-07-30 2020-07-28 Inhibidor de proteina quinasa quinasa activada por mitogeno (mek) para el tratamiento de apoplejia.

Country Status (11)

Country Link
US (1) US20220273660A1 (es)
EP (1) EP4003356A1 (es)
JP (1) JP2022542514A (es)
KR (1) KR20220106106A (es)
CN (1) CN114502169A (es)
AU (1) AU2020323687A1 (es)
BR (1) BR112022001678A2 (es)
CA (1) CA3146052A1 (es)
IL (1) IL290033A (es)
MX (1) MX2022001328A (es)
WO (1) WO2021018866A1 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2741896T3 (es) * 2012-03-14 2020-02-12 Lupin Ltd Compuestos de heterociclilo
WO2016009306A1 (en) * 2014-07-15 2016-01-21 Lupin Limited Heterocyclyl compounds as mek inhibitors

Also Published As

Publication number Publication date
KR20220106106A (ko) 2022-07-28
CA3146052A1 (en) 2021-02-04
US20220273660A1 (en) 2022-09-01
CN114502169A (zh) 2022-05-13
IL290033A (en) 2022-03-01
WO2021018866A1 (en) 2021-02-04
BR112022001678A2 (pt) 2022-05-03
JP2022542514A (ja) 2022-10-04
EP4003356A1 (en) 2022-06-01
AU2020323687A1 (en) 2022-02-17

Similar Documents

Publication Publication Date Title
CR20220351A (es) Inhibidores de proteínas kras mutantes
JOP20220008A1 (ar) مثبطات parp1
PH12020500396A1 (en) Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof
MX2021014441A (es) Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
MX2021014443A (es) Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
MX2020008271A (es) Inhibidor de fap.
MX2020007799A (es) Inhibidores de cinasa no derrepresible de control de aminoacido general 2 (gcn2) y sus usos.
MX2021001186A (es) Purinonas como inhibidores de proteasa especifica de ubiquitina 1.
MX2018010192A (es) Inhibidores de glucosidasa.
MX2018010191A (es) Inhibidores de glucosidasa.
CY1126067T1 (el) Συντηγμενες πυρρολινες που δρουν σαν ειδικοι για ουβικιτινη αναστολεις πρωτεασης 30 (usp30)
MX2022001004A (es) Inhibidores de enzimas.
MX2021008592A (es) Composiciones de trem y usos de las mismas.
WO2018153508A3 (en) INHIBITORS OF SULFOXIMINE GLYCOSIDASE
MX2021003843A (es) Inhibidores de la interaccion yap/taz-tead y su uso en el tratamiento del cancer.
MX2019010101A (es) Composiciones y metodos para promover el crecimiento del cabello con inhibidores de mpc1.
MX2022016066A (es) Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas.
WO2020123816A3 (en) Anellosomes and methods of use
MX2022006312A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos.
PH12020550222A1 (en) Gluconic acid derivatives for use in the treatment and/or prevention of microbial infections
MX2021015333A (es) Combinaciones de inhibidores para el tratamiento de enfermedades relacionadas con la expresion de dux4.
WO2020109233A3 (en) Trmt2a inhibitors for use in the treatment of polyglutamine diseases
MX2021006488A (es) Composiciones para mejorar la funcion sexual.
MX2022001328A (es) Inhibidor de proteina quinasa quinasa activada por mitogeno (mek) para el tratamiento de apoplejia.
WO2020086954A3 (en) Treatments for charcot-marie-tooth disease